Evaluating the Cost-Effectiveness of Medications for Type 2 Diabetes: An Interview With Jeffrey D. Dunn, PharmD, MBA
January 24, 2020
Jeffrey D. Dunn, PharmD, MBA, has served as vice president of clinical strategy and programs and industry relations at MagellanRx, a national pharmacy benefit manager (PBM); cofounder, senior vice president, chief clinical officer, and board member of VRx, a regional PBM; and pharmacy director of SelectHealth, part of Intermountain Healthcare. Dunn was instrumental in opening and running the VRx retail pharmacy in downtown Salt Lake City, Utah. He is a board member of Care Pharmacies Cooperative, a chain of 100 retail pharmacies.
An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Dunn regarding the recent Institute for Clinical and Economic Review report on the cost-effectiveness of oral semaglutide.